Immunome Inc (IMNM) financials
Immunome revenue and earnings by year
Immunome's revenue was $6.94 million in the fiscal year to December 31, 2025, down 23.2% from the year before. Net income was -$212 million, -3060.0% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 7 | 9 | 14 |
| Revenue growth | -23.2% | -35.5% | — |
| Operating income | -224 | -306 | -110 |
| Operating margin | -3228.8% | -3382.4% | -781.4% |
| Net income | -212 | -293 | -107 |
| Net margin | -3060.0% | -3240.4% | -761.9% |
| Diluted EPS | -$2.43 | -$5.00 | -$5.38 |
| Free cash flow | -201 | -118 | -8 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open IMNM in Markets.
See also: IMNM returns
No forecast, no recommendation. This page describes Immunome Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.